By PPN News Staff
The FDA approved Merck’s two doravirine-based HIV-1 medicines.
Delstrigo, a once-daily fixed-dose combination tablet of doravirine (DOR, 100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg); and Pifeltro (doravirine alone, 100 mg), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), will be administered in combination with other antiretroviral drugs.
Both DOR/3TC/TDF and DOR alone are indicated for the treatment of HIV-1